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| INTRODUC TI ON
Thyroid nodules are a common clinical problem. The estimated prevalence of palpable thyroid nodules is approximately 5% in women and 1% in men, while the prevalence of nonpalpable, ultrasonically detectable nodules is much higher. 1, 2 Several classification systems of thyroid nodules have been published based on ultrasound characteristics 1, 3, 4 but none of these recommendations have been validated with extensive prospective studies.
The international scoring systems have been evaluated by a meta-analysis of 10 437 nodules, 5 in which it was found that the classification proposed by Horvath and collaborators in 2009, 6 known as Thyroid Imaging Reporting and Data System (TIRADS) and subsequently modified by the French Society of Endocrinology in 2011 and renamed as the European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules (EU-TIRADS), validated by a large prospective study, 7 showed a good sensitivity and specificity (79% and 71%, respectively). Based on these considerations, EU-TIRADS has been adopted in the present case study as the ultrasound classification system. Thyroid fine needle cytology (FNC) has proven to be an accurate, safe, efficient and cost-effective diagnostic tool in patients with thyroid nodules. 8 Published data on FNC of thyroid nodules reported a sensitivity ranging from 65% to 98%, a specificity of 72%-100%, a positive predictive value of 34%-100% and a negative predictive value of 83%-100%. 9 Although most thyroid lesions are classified as TIR2 (benign) according to the new Italian consensus SIAPEC-AIT 2014 classification, 10 along with the main International cytological classifications (Bethesda System and The British Thyroid Association), some cases are more challenging than others and cannot be classified as benign or malignant on cytomorphological features only, leading to an indeterminate diagnosis.
In an attempt to improve accuracy in the indeterminate FNC category, several studies have evaluated different biological markers in thyroid FNC. Early immunohistochemical markers such as galectin-3, 11 HBME-1 12 and cytokeratin 19 13 have yielded less than optimal results. The relative low specificity and lack of reproducibility among different laboratories make immunohistochemical studies difficult to use as a daily diagnostic tool to differentiate benign from malignant thyroid lesions.
Advancements in molecular studies have allowed the identification of genetic alterations associated with different follicular cellderived neoplasms in thyroid. [14] [15] [16] Molecular tests on FNC samples significantly improve the accuracy of the cytological diagnosis of thyroid nodules, which could have a significant impact on clinical care. 9, 10, 17 A number of genetic mutations are associated with thyroid cancer. The most common genetic mutations in papillary thyroid carcinoma (PTC) are point mutations involving BRAF and RAS genes, while the most common chromosomal rearrangement is RET/PTC, which is involved in the mitogen-activated protein kinase (MAPK) pathway. [18] [19] [20] These mutations are found in more than 70% of PTCs, and most of the times, are mutually exclusive. 11, 13 RAS mutations or PAX8/PPARɣ rearrangement, which are mutually exclusive, occur in approximately 80% of follicular thyroid carcinomas (FTCs) 14 ; 60% of poorly differentiated and anaplastic tumours are due to mutations of BRAF and RAS genes. 21, 22 Medullary thyroid carcinomas (MTC) (both hereditary and sporadic types) frequently present point mutations in RET gene. In fact, MTC is transmitted in an autosomal-dominant pattern in multiple endocrine neoplasia (MEN) syndrome (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC). 15 In cases where cytological analysis of a given thyroid neoplasm is unable to formulate a definitive diagnosis, information on the presence of specific mutations related to thyroid carcinogenesis may be useful and may provide elements for a correct histological diagnosis. [22] [23] [24] The American Thyroid Association Guidelines (ATA) recognize the benefits of molecular markers in the management of thyroid cancer, also by the demonstration of new molecules that have helped to highlight the pathogenetic basis of thyroid cancer, although most of them are infrequently found. 1, 25 ATA guidelines recommend that molecular analyses should investigate seven genes, those mostly involved in thyroid carcinogenesis.
In the present study, by using pre-operative cytological samples, we looked for the most frequent mutations and/or rearrangements found in thyroid lesions (BRAF, RET/PTC1-3, RAS and PAX8/PPARɣ) in order to refine the cytopathologic diagnosis and to evaluate new possible therapeutic and prognostic targets for indeterminate, suspicious and frankly malignant thyroid nodules. DNA and/or RNA was extracted from FNC samples to identify a broader panel of genes whose mutations were related to approximately 70% of thyroid carcinomas to be studied by amplification and sequencing techniques.
| MATERIAL S AND ME THODS
A prospective study on 141 patients (104 women and 37 men) with ultrasonographically and clinically suspicious thyroid nodules was carried out. Each nodule was assigned a score from 2 to 5 according to EU-TIRADS system, 6 to stratify patients into different classes of risk of malignancy.
One hundred forty-one FNCs from thyroid nodules or secondary lesions of soft tissue and metastases of thyroid carcinoma were collected, among 2304 samples, at Istituto Nazionale dei Tumori -IRCCS These studies have been designed to standardize the PCR method, in order to carry out as many analyses as possible with the smallest amount of material possible. The tube was stored frozen at −80°C until DNA and RNA extraction was required. Samples were then processed for both DNA and RNA extraction using a Qiagen kit.
The DNA study was carried out by an innovative methodology that used two different multiplexes on DNA 26 : the first one for the simultaneous identification of seven different exons representing the most frequent point mutations of BRAF, H-N and K-RAS genes and the other one for the study of eight exons of RET gene, whose point mutations are associated with thyroid diseases.
RNA was reverse transcribed into cDNA as indicated in the Qiagen 'QuantiTect reverse transcription kit'. The housekeeping gene GAPDH, uniformly expressed in all cells, was amplified by PCR to verify that the quality of the RNA samples was suitable for molecular analyses. RET-PTC rearrangements 1 and 3 were detected by PCR amplification. A multiplex amplification of wild-type PAX8 and PAX8/PPARɣ rearrangement was also performed. 27 All DNA amplifications and only the cDNA that resulted positive for chromosomal rearrangements were purified and subjected to automatic sequencing with Sanger technique on both strands by capillary electrophoresis. This technique was carried out with a Life Technologies 3730 DNA Analyzer and, subsequently, the comparative analysis of the sequences was performed through a dedicated software, using a reference sequence without mutations (wild-type sequence). The analyses were then repeated on a new aliquot of material for the samples carrying mutations.
| RE SULTS

| Ultrasonographic features and cytological criteria of thyroid nodules
In the present case series, only mostly solitary nodules with indication for FNC according to EU-TIRADS were included. Of the 141 cases enrolled in this study, 13 cases were lymph node metastases to which no EU-TIRADS score was assigned. The remaining 128 cases were scored as follows: 58 as EU-TIRADS 3, of these, 20 were TIR2 and used as control cases for subsequent molecular investigations; 56 as EU-TIRADS 4; and 14 as EU-TIRADS 5.
The respective PPV and NPV relative to this ultrasound classification were 80% and 43%.
The combined US and cytomorphologic evaluation predictive values were, respectively, as follows: PPV 87% and NPV 88%. Positive  Adenoma  NIFTP  Negative  TOT   TIR3A  2  16  0  1  19   TIR3B  10  8  4  1  23   TIR4  16  2  0  0  18   TIR5  42  0  0  0  42   METASTASIS  13  0  0  13   TOT  83  26  4  2  115 Abbreviation: TOT, total number of tested samples. were considered as false positives) and 79% (if also the mutated cases that resulted adenomas on histology were considered as false positives); the NPV was 60%.
Cytological diagnosis
Histological diagnosis
| Mutational analysis
| Ultrasonographic, cytological, molecular and histological correlations
Of the 141 cases in our series, it was possible to cross-check the ultrasonographic, cytological, mutational and histological data in 103 cases. In this correlation, the cases lacking histopathological examination, the cases not suitable for molecular analyses and metastases (for which an EU-TIRADS value is generally not assigned) were not considered. The results are shown in Figure 2 . As far as the ultrasonographic data are concerned, the cases were divided into three large groups according to the assigned EU-TIRADS.
A total of 32 cases were EU-TIRADS 3 of which eight were TIR3A cytologically, 90% were mutated and 10% wild-type: all resulted adenomas at the subsequent histological examination; 11
were TIR3B cytologically, 90% were mutated, which turned out to be 50% adenomas and 50% carcinomas on histological examination, and the remaining 10% were wild-type, all resulted to be adenomas;
five were TIR4 cytologically, 80% were mutated and 20% wild-type, all resulted to be carcinomas; eight were TIR5 cytologically, 90%
were mutated and 10% wild-type, all of which turned out to be carcinomas.
A total of 42 cases were EU-TIRADS 4:8 were TIR3A cytologically, 90% were mutated, which resulted to be adenomas/hy- 
| D ISCUSS I ON
The first diagnostic approach of thyroid nodules is represented by ultrasound examination. The EU-TIRADS classification seems to be a valid tool in the radiologists' hands in order to identify those nodules with low, intermediate and high-risk ultrasound features for which FNC cytology is recommended.
Fine needle cytology is the most reliable diagnostic test for thyroid nodules, with a good accuracy and patients' compliance.
Although >90% of thyroid nodules are non-neoplastic, 10 In this study, we reported the results of a prospective molecular analysis on 141 cytological samples of thyroid nodules with an indeterminate or frankly malignant cytological diagnosis to attempt a better management of the patients. Although this study concerns a small case series compared to more extensive studies, [28] [29] [30] possibility to perform molecular tests with an innovative, easy and low-cost method.
Nikiforov and collaborators carried out a large prospective study on 967 FNC with indeterminate cytology. 28 According to these authors, the mutational testing using residual material obtained during routine FNCs allows more accurate cancer risk stratification of thyroid nodules with indeterminate cytology.
Several studies [31] [32] [33] Particularly, interesting is the data related to the study of RET gene polymorphisms that present a high-frequency value in the most aggressive forms according to Santos and collaborators. 34 It is generally possible to observe a much higher frequency of RET polymorphisms in TIR3B (all samples showed RET polymorphisms) compared to TIR3A (8/22 did not show RET polymorphisms).
This could be related to a different prognostic potential in these groups of lesions, but the small number of examined patients did not allow statistical evaluations. Hence, further studies could help in the discrimination of the two forms that currently represent the greatest criticality in the management of thyroid diseases. These studies could also clarify the possible correlation between the found polymorphisms and the patients' age and/or size of the neoplasm.
Moreover, they could shed further light on the sequence adenomacarcinoma and/or the relative risk of metastasis, as already reported in the literature or in studies relatively small or not associated with all possible thyroid diseases. 35 In our series, only one case showed the simultaneous presence of RET/PTC1 and RET/PTC3 rearrangements, which most likely caused the onset of a very peculiar composite malignancy. 36 At present, two new generation molecular tests are used: Afirma for gene expression study and Thyroseq system that can be used The proposed methodology has a low cost (about 250 euros per patient) and therefore it can be easily implemented by the National Healthcare System as well as in small laboratories, that do not have very sophisticated and expensive equipment and above all highly specialized personnel trained in complex bioinformatics systems, such as those employed in NGS technologies.
From the comparison of ultrasonographic, cytological, molecular and histological data a possible management of patients with thyroid nodules has emerged, distinguishing between candidates to surgery and patients who can simply be clinically followed.
Based on histological results, here we propose the following patient management (Figure 3 ): for those who are EU-TIRADS 3 on ultrasound examination and TIR3A cytologically, with or without mutation (mutated/wild type), a clinical and instrumental follow-up is suggested; the same applies to not mutated (wild type) TIR3B.
Histologically, these cases were benign lesions. For patients who are diagnosed as TIR3B, TIR4 and TIR5 cytologically, in which a mutation is identified, surgery is suggested: they all showed a thyroid carcinoma at the subsequent histology.
For EU-TIRADS 4 patients, cytologically TIR3A, TIR3B, TIR4, TIR5, in which a mutation is identified, surgery is suggested. They all showed a thyroid carcinoma at the subsequent histology. For patients diagnosed as TIR3A cytologically, who are wild-type, a followup is suggested because they resulted to be, in our series, benign lesions on histological examination.
For EU-TIRADS 5 patients, who were cytologically diagnosed as TIR3A, TIR3B, TIR4, TIR5, and, in which a mutation is identified, surgery is necessary. All cases were thyroid carcinomas on histology.
Based on our results, hemithyroidectomy could be suggested only in EU-TIRADS 3/TIR3B/mutated cases, as in 50% of cases they resulted to be adenomatous lesions, with a possible completion thyroidectomy in cases of carcinoma. For all other cases, total thyroidectomy should be recommended.
In thyroid nodules with indeterminate cytology, the refinement of the pre-operative diagnosis is also a necessary step to optimize and economize the diagnostic and therapeutic pathway, avoiding unnecessary surgery.
A multidisciplinary approach to the thyroid nodules which comprises the surgeon, the radiologist, the pathologist and the molecular biologist is therefore necessary to develop innovative methods suitable for an improved diagnostic and prognostic definition of thyroid cancer.
